BioSpace News Archive

Alnylam Pharmaceuticals, Inc. announced today positive results from the 6-month primary analysis of the ILLUMINATE-C Phase 3 open-label study of lumasiran, an RNAi therapeutic targeting hydroxyacid oxidase 1

GlaxoSmithKline plc (LSE/NYSE: GSK) today announced positive results from the Phase III ASCEND (Anaemia Studies in Chronic Kidney Disease:

Blueprint Medicines Corporation announced that, effective on November 1, 2021, the Compensation Committee of Blueprint Medicines’ Board of Directors granted non-qualified stock options to purchase an aggregate of 24,373 shares of its common stock and an aggregate of 12,183 restricted stock units to eighteen new employees under Blueprint Medicines’ 2020 Inducement Plan.

atai Life Sciences N.V. today announced that it will participate in the following upcoming investor conferences in November:

The incidence of heart diseases is growing at a rapid pace around the world. The World health Organization states cardiovascular diseases as the leading cause of death across the globe.

In recent months, there is a striking increase in the spread of COVID-19 infection in all worldwide locations.

Diabetes-related eye diseases have attracted enormous attention of the healthcare community at large and primary care providers engaged in classification, diagnosis, and treatment.

Inventive technologies and cutting-edge research have led to the development of several innovative magnetic resonance imaging equipment, helping patients live healthier and longer lives.

Growing worldwide population living with numerous disease conditions is projected to stimulate fabulous demand opportunities in the US therapeutic plasma exchange market during 2019–2029.

Rising government assistance for clinical trials and research is expected to boost demand in the global Vaccine Storage Equipment Market in near future.